NCT06497270View on ClinicalTrials.gov

A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial

NAActive, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

October 10, 2024

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
BRCA MutationEstrogen DeficiencySurgical MenopauseMenopause Related ConditionsMenopause, PrematureOvarian Cancer
Interventions
PROCEDURE

Theca and Granulosa Cell Isolation

These patients will receive standard procedure during the risk reducing surgery but their ovaries will be used to extract theca and granulosa cells which will be used for the 3D bioprinted device's realisation.

Trial Locations (1)

00168

Day Hospital Tumori Femminili, Policlinico Universitario Fondazione Agostino Gemelli, IRCCS, Rome

All Listed Sponsors
lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

NCT06497270 - A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial | Biotech Hunter | Biotech Hunter